Injection site reactions with the HIV-1 fusion inhibitor enfuvirtide - 29/08/11
, Tosca Kinchelow, MD bISR Substudy Group
Abstract |
Background |
Enfuvirtide is the first of a new class of antiretroviral agents for the treatment of HIV-1 infection, called the fusion inhibitors. The most common type of adverse event associated with enfuvirtide treatment is injection site reactions, occurring in up to 98% of patients. Many of these lesions are symptomatic. This study investigated injection site reactions occurring in 7 patients with HIV infection who were receiving enfuvirtide.
Observations |
All biopsy specimens revealed an inflammatory response consistent with a localized hypersensitivity reaction; this was regardless of type of clinical lesion and included the patient with no clinical reaction. The pattern of inflammation resembled that of granuloma annulare and the recently described interstitial granulomatous drug reaction. Immunoperoxidase staining indicated that the inflammatory and collagen changes were greatest in areas where enfuvirtide was deposited.
Conclusions |
The pathologic changes and clinicopathologic correlations associated with injection site reactions in human enfuvirtide recipients have been described for the first time. This information also provides valuable insights into unusual pathogenic response to foreign antigens for patients with HIV.
Le texte complet de cet article est disponible en PDF.Plan
 | Members of the ISR Substudy Group: Nicholaos C. Bellos, MD, Andy Longoria, Dennis Williams, Farhad Niroomand, MD, and Jennifer Adams (Dallas, Tex); Judith E. Feinberg, MD, Patty Kohler, Diya Mutasim, MD, and Janice Brogden (University of Cincinnati Medical Center, Ohio); Michael Lederman, MD, Michael Chance, Lian Jie-Li, MD, and Janet Petro (University Hospital of Cleveland, Ohio); and Tina Monti and Dan Weihmiller (Roche, NJ). Supported in part by Hoffmann-La Roche, Nutley, NJ. Disclosure: Dr Ball is a consultant for Hoffmann-La Roche. |
Vol 49 - N° 5
P. 826-831 - novembre 2003 Retour au numéro
Article précédent
- CD4+ T-cell–directed antibody responses are maintained in patients with psoriasis receiving alefacept: results of a randomized study
- Alice B Gottlieb, Thomas B Casale, Ellen Frankel, Bernard Goffe, Nicholas Lowe, Hans D Ochs, Janet L Roberts, Ken Washenik, Akshay K Vaishnaw, Kenneth B Gordon
- Epidemiology of primary Merkel cell carcinoma in the United States
- Maria Agelli, Limin X Clegg
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?